Prostate Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
IRB13-0756 Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards
IRB13-0692 A Phase II Study of Recombinant Glycosylated Human Interluekin-7 (CYT 107) after Completion of Standard FDA Approved Therapy with Sipuleugel-T (Provenge) for Patients with Asyptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)
14934A Radiotherapy for Prostate Cancer: Dosimetric and Clinical Outcomes in the IMRT Era
12278A Clinical Urology Research Screening Protocol
Select
IRB14-0105 A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3
Select
15244B IRB 15244B: CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
10-625-A A feasibility study of oral hormonal therapy and radiation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with medical comorbidities
11-0061 Evaluation of endorectal MRI for risk stratification, treatment planning, and workup after biochemical failure in patients with adenocarcinoma of the prostate
Select
12-2086 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Select
IRB14-0105 A Phase 1, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3
IRB15-0496 A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)
Select
12-0109 NCI 9012: A Randomized Gene Fusion Stratified Phase II Trial of Abiraterone with or without ABT-888 for Patients with Metastatic Castration-Resistant Prostate Cancer
10-174-B Feasibility of Collection & Analysis of Circulating and Disseminated Tumor Cells from men with Advanced Prostate Cancer
Select
11-0110 CALGB 70807: The Mens Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
Select
IRB13-0979 A Phase I/II Trial of Enzalutamide plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients with Metastatic Castration Resistant Prostate Cancer (CRPC)
Select
CIRB14-0811 NRG-BR001: Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
12803B Quality of Life after Radical Prostatectomy
Select
11-0709 A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men with Castrate Resistant Prostate Cancer
Select
IRB13-0774 Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) vs. Bleomycin, Etoposide and Cisplatin (BEP) for Patients with Previously Untreated Intermediate and Poor-Risk Germ Cell Tumors
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
IRB15-0091 An Open-label, Dose-escalation/expansion, Phase 1 Study of ASP4132, Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team